Kolexia
Leary Alexandra Oncologie médicale
Leary Alexandra
Oncologie médicale
Gustave-Roussy
Villejuif, France
384 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinomes Carcinome épithélial de l'ovaire Tumeurs de l'endomètre Récidive tumorale locale Tumeurs du col de l'utérus Tumeurs de la trompe de Fallope Tumeurs du péritoine Tumeurs du sein

Collaborateurs

Voir plus
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France
Genestie Catherine
Genestie Catherine
Gustave-Roussy, Villejuif, France
Gouy Sebastien
Gouy Sebastien
Gustave-Roussy, Villejuif, France
Morice Philippe
Morice Philippe
Gustave-Roussy, Villejuif, France

Industries

Voir plus
MSD
24 collaboration(s)
Dernière en 2023
GSK
10 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023
PUBLICLIN
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
BEATcc: A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Essai Clinique (Grupo Español de Investigación en Cáncer de Ovario)   04 mars 2024
DOMENICA: Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Essai Clinique (GSK)   28 février 2024
SOLO-1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Essai Clinique (AstraZeneca)   28 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158): A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Essai Clinique (Merck & Co.)   02 février 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Annals of oncology : official journal of the European Society for Medical Oncology   01 février 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc   06 janvier 2024
The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology.
Lancet (London, England)   08 décembre 2023
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet (London, England)   01 décembre 2023